INS and type 2 diabetes mellitus: The QWINT-3 trial (NCT05275400), which had the longest treatment duration trial among the studies conducted on once-weekly insulins, evaluated efsitora in 986 individuals with type 2 diabetes inadequately controlled on basal insulin (4).